Effects of heparin and related drugs on neutrophil function

Pulmonary Pharmacology and Therapeutics

Volumn 25, Issue 2, 2012, Pages 185-192

  Brown, R A ^a   Leung, E ^a   Kankaanranta, H ^b,c   Moilanen, E ^b   Page, C P ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c SEINÄJOKI CENTRAL HOSPITAL   (Finland)

Author keywords

Anti Inflammatory; Apoptosis; Chronic obstructive pulmonary disease; FMLP; Heparin; IP 3

Indexed keywords

ENZYME ACTIVATOR; FAS ANTIBODY; INOSITOL 1,4,5 TRISPHOSPHATE RECEPTOR; LEUKOCYTE ELASTASE; LIPOCORTIN 5; LOW MOLECULAR WEIGHT HEPARIN; M 3M3FBS; THAPSIGARGIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BRONCHUS MUCOSA; CELL FUNCTION; CELL ISOLATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN EXPRESSION; VENOUS BLOOD;

ANNEXIN A5; ANTICOAGULANTS; APOPTOSIS; BRONCHI; EPITHELIAL CELLS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; LEUKOCYTE ELASTASE; NEUTROPHILS; SULFONAMIDES; THAPSIGARGIN; TIME FACTORS;

EID: 84862790072     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2012.01.006     Document Type: Article

References (31)

1. Lam L.H., Silbert J.E., Rosenberg R.D. The separation of active and inactive forms of heparin. Biochem Biophys Res Commun 1976, 69:570-577.
2. Lever R., Page C. Glycosaminoglycans, airways inflammation and bronchial hyperresponsiveness. Pulm Pharmacol Ther 2001, 14:249-254.
3. Lever R., Page C.P. Novel drug development opportunities for heparin. Nat Rev Drug Discov 2002, 1:140-148.
4. Chande N., McDonald J.W., Macdonald J.K., Wang J.J. Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010, [CD006774].
5. Brown R.A., Lever R., Jones N.A., Page C.P. Effects of heparin and related molecules upon neutrophil aggregation and elastase release in vitro. Br J Pharmacol 2003, 139:845-853.
6. Parsons C.L. Current strategies for managing interstitial cystitis. Expert Opin Pharmacother 2004, 5:287-293.
7. Brown R.A., Allegra L., Matera M.G., Page C.P., Cazzola M. Additional clinical benefit of enoxaparin in COPD patients receiving salmeterol and fluticasone propionate in combination. Pulm Pharmacol Ther 2006, 19:419-424.
8. Ghosh T.K., Eis P.S., Mullaney J.M., Ebert C.L., Gill D.L. Competitive, reversible, and potent antagonism of inositol 1,4,5-trisphosphate-activated calcium release by heparin. J Biol Chem 1988, 263:11075-11079.
9. Fasolato C., Hoth M., Matthews G., Penner R. Ca2+ and Mn2+ influx through receptor-mediated activation of nonspecific cation channels in mast cells. Proc Natl Acad Sci U S A 1993, 90:3068-3072.
10. Tones M.A., Bootman M.D., Higgins B.F., Lane D.A., Pay G.F., Lindahl U. The effect of heparin on the inositol 1,4,5-trisphosphate receptor in rat liver microsomes. Dependence on sulphate content and chain length. FEBS Lett 1989, 252:105-108.
11. Jonas S., Sugimori M., Llinas R. Is low molecular weight heparin a neuroprotectant?. Ann N Y Acad Sci 1997, 825:389-393.
12. Hauser C.J., Fekete Z., Adams J.M., Garced M., Livingston D.H., Deitch E.A. PAF-mediated Ca2+ influx in human neutrophils occurs via store-operated mechanisms. J Leukoc Biol 2001, 69:63-68.
13. Prossnitz E.R., Ye R.D. The N-formyl peptide receptor: a model for the study of chemoattractant receptor structure and function. Pharmacol Ther 1997, 74:73-102.
14. Barzu T., Molho P., Tobelem G., Petitou M., Caen J. Binding and endocytosis of heparin by human endothelial cells in culture. Biochim Biophys Acta 1985, 845:196-203.
15. Akimoto H., Ito H., Tanaka M., Adachi S., Hata M., Lin M., et al. Heparin and heparan sulfate block angiotensin II-induced hypertrophy in cultured neonatal rat cardiomyocytes. A possible role of intrinsic heparin-like molecules in regulation of cardiomyocyte hypertrophy. Circulation 1996, 93:810-816.
16. Savage J.M., Gilotti A.C., Granzow C.A., Molina F., Lowe-Krentz L.J. Antibodies against a putative heparin receptor slow cell proliferation and decrease MAPK activation in vascular smooth muscle cells. J Cell Physiol 2001, 187:283-293.
17. Manaster J., Chezar J., Shurtz-Swirski R., Shapiro G., Tendler Y., Kristal B., et al. Heparin induces apoptosis in human peripheral blood neutrophils. Br J Haematol 1996, 94:48-52.
18. Erduran E., Tekelioglu Y., Gedik Y., Yildiran A. Apoptotic effects of heparin on lymphoblasts, neutrophils, and mononuclear cells: results of a preliminary in vitro study. Am J Hematol 1999, 61:90-93.
19. Whyte M.K., Meagher L.C., MacDermot J., Haslett C. Impairment of function in aging neutrophils is associated with apoptosis. J Immunol 1993, 150:5124-5134.
20. Puchelle E., Zahm J.M., Tournier J.M., Coraux C. Airway epithelial repair, regeneration, and remodeling after injury in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006, 3:726-733.
21. Zhang X., Moilanen E., Adcock I.M., Lindsay M.A., Kankaanranta H. Divergent effect of mometasone on human eosinophil and neutrophil apoptosis. Life Sci 2002, 71:1523-1534.
22. Kankaanranta H., Ilmarinen P., Zhang X., Nissinen E., Moilanen E. Antieosinophilic activity of orazipone. Mol Pharmacol 2006, 69:1861-1870.
23. Capila I., VanderNoot V.A., Mealy T.R., Seaton B.A., Linhardt R.J. Interaction of heparin with annexin V. FEBS Lett 1999, 446:327-330.
24. Fryer A., Huang Y.C., Rao G., Jacoby D., Mancilla E., Whorton R., et al. Selective O-desulfation produces nonanticoagulant heparin that retains pharmacological activity in the lung. J Pharmacol Exp Ther 1997, 282:208-219.
25. Redini F., Tixier J.M., Petitou M., Choay J., Robert L., Hornebeck W. Inhibition of leucocyte elastase by heparin and its derivatives. Biochem J 1988, 252:515-519.
26. Walsh R.L., Dillon T.J., Scicchitano R., McLennan G. Heparin and heparan sulphate are inhibitors of human leucocyte elastase. Clin Sci (Lond) 1991, 81:341-346.
27. Lafuma C., Frisdal E., Harf A., Robert L., Hornebeck W. Prevention of leucocyte elastase-induced emphysema in mice by heparin fragments. Eur Respir J 1991, 4:1004-1009.
28. Rao N.V., Kennedy T.P., Rao G., Ky N., Hoidal J.R. Sulfated polysaccharides prevent human leukocyte elastase-induced acute lung injury and emphysema in hamsters. Am Rev Respir Dis 1990, 142:407-412.
29. Jones H., Paul W., Page C.P. A comparison of allergen and polycation induced cutaneous responses in the rabbit. Br J Pharmacol 2001, 133:1181-1189.
30. Baici A. Graphical and statistical analysis of hyperbolic tight-binding inhibition. Biochem J 1987, 244:793-796.
31. Bode W., Wei A.Z., Huber R., Meyer E., Travis J., Neumann S. X-ray crystal structure of the complex of human leukocyte elastase (PMN elastase) and the third domain of the turkey ovomucoid inhibitor. EMBO J 1986, 5:2453-2458.